---
document_datetime: 2025-12-02 10:09:11
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/krazati-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: krazati-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.5704742
conversion_datetime: 2025-12-21 20:15:24.878918
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Krazati

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0010/G            | This was an application for a group of variations. A grouped application consisting of: C.I.4: Submission of results from study 849-012 (KRYSTAL-12) listed as a specific obligation in the | 27/03/2025                          | 17/11/2025                                  | SmPC, Annex II and PL            | SmPC new text Update of section 4.8 of the SmPC based on an integrated analysis of safety data from interventional studies 849-012 (KRYSTAL-12), 849-007 (KRYSTAL-7) and 849-001 (KRYSTAL-1). Frequencies percentages of existing adverse reactions have been revised. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | Annex II. This is a Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation. Annex IIE has been updated accordingly. The RMP version 2.1 is agreed. The MAH took the opportunity to make editorial changes to the SmPC and package leaflet. C.I.4: Update of section 4.8 of the SmPC in order to update safety information based on an integrated analysis of data from interventional studies 849-012 (KRYSTAL-12), 849-007 (KRYSTAL-7) and 849-001 (KRYSTAL-1). The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            | For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                        |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/214/2 02406 | Periodic Safety Update EU Single assessment - adagrasib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16/01/2025 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                    |
| R/0006            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 19/09/2024 | 18/11/2024 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Krazati, subject to the |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                 |            |            |                 | Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------|
| IB/0004   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                    | 03/09/2024 | n/a        |                 |                                                                                |
| IAIN/0009 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                          | 30/08/2024 | 18/11/2024 | Annex II and PL |                                                                                |
| IA/0007/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits | 16/08/2024 | n/a        |                 |                                                                                |
| IB/0005   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                    | 15/07/2024 | n/a        |                 |                                                                                |
| IAIN/0003 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                  | 21/05/2024 | 18/11/2024 | SmPC and PL     |                                                                                |

<div style=\"page-break-after: always\"></div>

| T/0002    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 04/04/2024   | 25/04/2024   | SmPC, Labelling and PL   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
| IA/0001/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 12/03/2024   | n/a          |                          |